Orion gives up on early use of Stalevo in Parkinson's in the EU
This article was originally published in Scrip
Executive Summary
Orion has decided to withdraw its EU application for extending the indication for Orion and Novartis's Parkinson's disease treatment, Stalevo (a combination formulation of carbidopa, levodopa and entacapone), following last month's failure of the STRIDE-PD trial, investigating it as a first-line treatment.